Search Results
Your search for Matthew Stenger,Matthew Stenger matches 7242 pages
Showing 1 - 50Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival?
Results from the Prognostic Immunophenotyping in Myeloma Response (PRIMeR) study, reported in the Journal of Clinical Oncology by Marcelo C. Pasquini, MD, MS, and colleagues, found that undetectable measurable residual disease (MRD) status at 1 year after autologous hematopoietic cell...
Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer: Comparison of Agents
In a Chinese phase III trial (CRTCOESC) reported in the Journal of Clinical Oncology, Jia et al found that neither capecitabine nor XELOX (capecitabine, oxaliplatin) improved 2-year overall survival vs cisplatin/fluorouracil as part of definitive concurrent chemoradiotherapy in patients with...
Donepezil for the Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy
In the phase III WF-97116 trial reported in the Journal of Clinical Oncology, Rapp et al found that treatment with the cognitive enhancer donepezil did not improve memory or other cognitive functions vs placebo in breast cancer survivors with cancer-related cognitive impairment 1 to 5 years after...
Previously Untreated Mantle Cell Lymphoma: Ibrutinib, Immunochemotherapy, and ASCT
As reported in The Lancet by Martin Dreyling, MD, PhD, and colleagues, results in the European Mantle Cell Lymphoma Network phase III TRIANGLE trial indicate that the addition of ibrutinib to immunochemotherapy and autologous stem cell transplantation (ASCT) significantly improved failure-free...
Marker for Distinguishing Renal Cell Carcinoma From Benign Renal Masses
In a study reported in the Journal of Clinical Oncology, Xu et al found that higher levels of preoperative plasma kidney injury molecule-1 (pKIM-1) distinguished renal cell carcinoma from benign renal masses. As stated by the investigators, “Both clear cell and papillary renal cell carcinoma...
T-DXd for Advanced Solid Tumors With Activating HER2 Mutations
As reported in The Lancet Oncology by Bob T. Li, MD, PhD, MPH, and colleagues, the phase II DESTINY-PanTumor01 trial showed activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with unresectable or metastatic solid tumors that have specific activating HER2 mutations. The antibody-drug...
Childhood Cancer Survivors: Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus
In a study reported in the Journal of Clinical Oncology, Im et al found that genetic variants associated with a risk of treatment-related type 2 diabetes mellitus among childhood cancer survivors of African or European ancestry posed a higher risk of diabetes among those of African ancestry. As...
Lymphoid Neoplasms: European National Health Expenditure and Long-Term Survival
In an analysis of the EUROCARE-6 data set reported in The Lancet Oncology, Milena Sant, MD, and colleagues found that patients with lymphoid neoplasms from European countries with greater health expenditure had improved 10-year age-standardized relative survival. Study Details The study involved...
Doublet for Previously Treated Patients With Advanced Leiomyosarcoma
In a phase Ib study reported in the Journal of Clinical Oncology, Van Tine et al established the recommended phase II dose of oral unesbulin in combination with dacarbazine for patients with locally recurrent, unresectable or metastatic, relapsed or refractory leiomyosarcoma. Unesbulin is a small...
Pirtobrutinib in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
On December 1, 2023, pirtobrutinib (Jaypirca), a selective, noncovalent Bruton’s tyrosine kinase (BTK) inhibitor that inhibits both wild-type and C481-mutant BTK with equal low nanomolar potency and is designed to address several of the limitations of covalent BTK inhibitors, was granted...
Pembrolizumab/Chemotherapy for Advanced Biliary Tract Cancer
On October 31, 2023, pembrolizumab (Keytruda) was approved for use with gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on the double-blind KEYNOTE-966 trial...
Belzutifan in Previously Treated Advanced Renal Cell Carcinoma
On December 14, 2023, the hypoxia-inducible factor inhibitor belzutifan (Welireg) was approved for patients with unresectable locally advanced or metastatic clear cell renal cell carcinoma with disease progression on previous treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial...
Enfortumab Vedotin-ejfv Plus Pembrolizumab Improves Survival vs Platinum-Based Chemotherapy in Advanced Urothelial Cancer
As reported in The New England Journal of Medicine by Thomas Powles, MD, Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody–drug conjugate enfortumab vedotin-ejfv, which is...
Cell-Free DNA Blood-Based Test and Next-Generation Multitarget Stool DNA Test in Colorectal Cancer Screening
In two studies reported in The New England Journal of Medicine, investigators found that a cell-free DNA (cfDNA) blood-based test (ECLIPSE study)1 and a next-generation multitarget stool DNA test (BLUE-C study)2 both showed high sensitivity for colorectal cancer and high specificity for advanced...
Whole-Pelvic Radiation Therapy for Unfavorable-Risk Prostate Cancer
As reported in the Journal of Clinical Oncology by Sayan et al, analysis of long-term findings from the phase III Dana-Farber Cancer Institute Trial 05-043 showed that whole-pelvic radiation therapy (WPRT) was associated with favorable survival outcomes vs prostate-only radiation therapy (PORT)...
Head and Neck Cancer: Osteoradionecrosis of the Jaw Classification System
In a single-institution study reported in the Journal of Clinical Oncology, Watson et al identified risk factors for osteoradionecrosis of the jaw and developed a classification system for the condition in patients receiving radiation therapy for head and neck cancer. Study Details The study...
Impact of Age on Outcomes in Endometrial Cancer
In an analysis of data from the PORTEC-1, -2, and -3 trials reported in The Lancet Oncology, Wakkerman et al found that older age was associated with more aggressive tumor features and poorer outcomes in patients with endometrial cancer. Study Details The analysis included data from 1,801...
Addition of Durvalumab to Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer: PROs in TOPAZ-1
As reported in The Lancet Oncology by Howard A. Burris III, MD, FACP, FASCO, and colleagues, a patient-reported outcome (PRO) analysis from the phase III TOPAZ-1 trial showed no “detrimental effect” with the addition of durvalumab to gemcitabine/cisplatin in patients with advanced biliary tract...
Omission of Axillary Dissection After Nodal Downstaging With Neoadjuvant Chemotherapy in Breast Cancer
In a retrospective cohort study reported in JAMA Oncology, Montagna et al found that patients with breast cancer with nodal downstaging after neoadjuvant chemotherapy had a low rate of axillary recurrence, with no difference observed for staging with targeted axillary dissection vs sentinel lymph...
Local Recurrence of Endometrial Cancer: Radiotherapy With or Without Cisplatin
As reported in the Journal of Clinical Oncology by Ann H. Klopp, MD, PhD, and colleagues, results from an NRG Oncology/GOG trial showed “excellent” progression-free survival outcomes with radiation therapy alone for local recurrences of endometrial cancer, with the addition of cisplatin in...
Hemihepatectomy: Outcomes With Laparoscopic vs Open Surgery
In a phase III study (ORANGE II PLUS) reported in the Journal of Clinical Oncology, Fichtinger et al found that among patients with indications for hemihepatectomy suitable for both laparoscopic and open approaches, of whom the majority had cancer, the laparoscopic approach was associated with a...
T-DXd vs Physician’s Choice of Therapy in HER2-Positive Metastatic Breast Cancer: PROs in DESTINY-Breast02
In an analysis of patient-reported outcomes (PROs) in the DESTINY-Breast02 trial published in The Lancet Oncology, Tanja Fehm, MD, and colleagues found that general health status/quality of life was maintained over time with fam-trastuzumab deruxtecan-nxki (T-DXd) vs physician’s choice of therapy...
Dato-DXd in Advanced or Metastatic HR-Positive/HER2-Negative or Triple-Negative Breast Cancer
In the phase I TROPION-PanTumor01 trial reported in the Journal of Clinical Oncology, Aditya Bardia, MD, PhD, and colleagues found that the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) was active in patients with locally advanced or metastatic hormone receptor...
Durvalumab After Chemoradiotherapy in Unresectable NSCLC: Real-World Use and Outcomes
In a U.S. retrospective cohort study (SPOTLIGHT) reported in JAMA Network Open, Mooradian et al found that a substantial proportion of patients with unresectable stage III non–small cell lung cancer (NSCLC) did not receive consolidation durvalumab after chemoradiotherapy—but those who did had...
United Kingdom’s First Cardio-Oncology Service: 10-Year Experience
In a research letter published by Andres et al in JACC: CardioOncology, staff from Royal Brompton Hospital, Guy’s and St. Thomas’ NHS Foundation Trust in London described their experience over 10 years in the UK’s first cardio-oncology service. Study Details The study involved data from the initial ...
Relapsed or Refractory CD7-Positive Leukemia or Lymphoma: CAR T-Cell Therapy Plus HSCT Without GVHD Prophylaxis
In a Chinese study reported in The New England Journal of Medicine, Hu et al found that sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and allogeneic hematopoietic stem cell transplantation (HSCT) without graft-vs-host disease (GVHD) prophylaxis was effective in patients with...
Premastectomy Radiotherapy, Surgery, and Immediate Breast Reconstruction
In a single-center phase II trial reported in JAMA Network Open, Schaverien et al found that a strategy of premastectomy radiotherapy and immediate breast reconstruction was feasible in patients undergoing surgery for breast cancer. Study Details A total of 49 patients with cT0–T3, N0–N3b breast...
Liposomal Irinotecan vs Topotecan in Relapsed Small Cell Lung Cancer
As reported in the Journal of Clinical Oncology by David R. Spigel, MD, and colleagues, the phase III RESILIENT Part 2 trial has shown no overall survival benefit with second-line liposomal irinotecan vs topotecan in patients with small cell lung cancer whose disease progressed on or after...
Risk of Arterial Thromboembolism in Japanese Patients With Cancer
In a Japanese retrospective study reported in JACC:CardioOncology, Gon et al identified the incidence and outcomes of arterial thromboembolism in patients with cancer. Study Details The study used data on 97,448 patients with cancer (median age = 70 years) from the Osaka Cancer Registry linked with ...
Metastatic Urothelial Cancer: NECTIN4 Amplification and Response to Enfortumab Vedotin
In a study reported in the Journal of Clinical Oncology, Klümper et al established a fluorescence in situ hybridization (FISH) assay to measure NECTIN4 copy number variations and found that NECTIN4 amplification was associated with high activity of the anti-NECTIN4 antibody-drug conjugate...
Salvage Reirradiation for Locally Recurrent Prostate Cancer: 7-Year Follow-up
In an update of a Norwegian trial reported in the Journal of Clinical Oncology, Ekanger et al found that long term, salvage reirradiation for locally recurrent prostate cancer was feasible and associated with good outcomes. Study Details The study included 38 patients with locally recurrent disease ...
Metastatic Castration-Resistant Prostate Cancer: Addition of LuPSMA to Enzalutamide
In an interim analysis of the Australian phase II ENZA-p trial reported in The Lancet Oncology, Emmett et al found that the addition of lutetium-177–labeled PSMA-617 (LuPSMA) to enzalutamide improved prostate-specific antigen (PSA) progression-free survival in the first-line treatment of patients...
Pediatric AML: Comparison of Induction Regimens
In the phase III AML2012 trial, which had early termination of enrollment and results of which were reported in the Journal of Clinical Oncology, Tierens et al found that mitoxantrone-based induction resulted in better outcomes vs liposomal daunorubicin–based induction in pediatric patients with...
Older Patients With Newly Diagnosed Hodgkin Lymphoma: Preexisting Heart Failure and Survival Outcomes
In a study reported in JACC: CardioOncology, Upshaw et al found that preexisting heart failure was associated with an increased risk of lymphoma and cardiovascular mortality among patients aged ≥ 65 years who were newly diagnosed with Hodgkin lymphoma. The study used linked Surveillance,...
Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk ALL
In an analysis from the Children’s Oncology Group phase III AALL1131 study reported in the Journal of Clinical Oncology, Alexander et al found that exposure to propofol was associated with an increased risk of impairment in reaction time/processing speed at 1 year after treatment in children with...
Neoadjuvant Chemoimmunotherapy in Patients With Early-Stage NSCLC
In a systematic review and meta-analysis reported in JAMA Network Open, Banna et al found that neoadjuvant chemoimmunotherapy was associated with improved event-free survival and pathologic complete response compared with neoadjuvant chemotherapy alone in patients with early-stage non–small cell...
MRI-Guided Duration of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
In a Dutch phase II study (TRAIN-3) reported in The Lancet Oncology, Anna van der Voort, MD, and colleagues found that magnetic resonance imaging (MRI) detected complete radiologic response after only three cycles of neoadjuvant chemotherapy in many patients with stage II to III HER2-positive...
Immunotherapy Plus FOLFIRI for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
In a French noncomparative phase II trial (PRODIGE 59-FFCD 1707-DURIGAST) reported in JAMA Oncology, Tougeron et al found limited activity of FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus durvalumab or durvalumab/tremelimumab in the second-line treatment of advanced...
Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, FASCO, and colleagues, the third prespecified interim analysis of overall survival in the phase III KEYNOTE-564 trial has shown a significant benefit with adjuvant pembrolizumab vs placebo in patients with clear cell renal...
Combined ICI and VEGF Inhibitor Trials in Cancer: Cardiovascular Eligibility Criteria and Adverse Event Reporting
In a study reported in JACC:CardioOncology, Rankin et al analyzed the degree to which published phase II to IV trials of combination immune checkpoint inhibitor (ICI) and VEGF inhibitor treatment for cancer reported cardiovascular eligibility criteria and adverse events. As stated by the...
Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy
In a study reported in a research letter in JAMA Oncology, Storgard et al identified the risk of T-cell malignant neoplasms and any second primary malignant neoplasms in patients receiving chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Study Details The study used...
Zanubrutinib in Relapsed or Refractory Follicular Lymphoma
On March 7, 2024, the Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa) was granted accelerated approval in combination with the monoclonal antibody obinutuzumab for patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.1 Supporting Efficacy...
In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer
In a UK-based prospective cohort study reported in The Lancet Oncology, Turtle et al found that among patients hospitalized due to COVID-19 infection, those receiving cancer treatment had a higher rate of in-hospital mortality vs those without a cancer diagnosis. Study Details The study included...
Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Barker et al found that induction treatment with vismodegib followed by concurrent treatment with vismodegib and curative-intent radiation therapy showed efficacy in patients with locally advanced unresectable basal cell carcinoma. ...
Cabozantinib in Metastatic Pheochromocytomas or Paragangliomas
In the single-center phase II Natalie trial reported in The Lancet Oncology, Jimenez et al found that cabozantinib was active in patients with unresectable and progressive metastatic pheochromocytomas or paragangliomas (MPPGs). As stated by the investigators: “Up to 50% of MPPGs are associated with ...
Nivolumab With or Without Ipilimumab in Recurrent or Metastatic Cervical Cancer
As reported in The Lancet Oncology by Ana Oaknin, MD, of the Medical Oncology Service at Vall d´Hebron Institute of Oncology, Vall d´Hebron Barcelona Hospital, and colleagues, the phase I/II CheckMate 358 trial showed that both nivolumab monotherapy and nivolumab/ipilimumab regimens were active...
Functional Disability Among U.S. Cancer Survivors, 2017–2022
In a study reported in the Journal of Clinical Oncology, Cao et al found that U.S. adult cancer survivors had higher levels of mobility disability and self-care disability than adults without a cancer diagnosis. Study Details The study focused on data from 47,768 adult cancer survivors (aged ≥ 18...
Risk of Second Primary Breast Cancer in Young Breast Cancer Survivors
In a study reported in JAMA Oncology, Kristen D. Brantley, PhD, MPH, and colleagues identified the risk of a second primary breast cancer among survivors of breast cancer diagnosed at age 40 or younger, including among women with and without germline pathogenic variants. Study Details The study...
Cisplatin, Gemcitabine, and IMRT in Locally Advanced Vulvar Cancer
In a phase II trial (NRG Oncology/GOG Study 279) reported in the Journal of Clinical Oncology, Horowitz et al found that concurrent cisplatin, gemcitabine, and intensity-modulated radiation therapy (IMRT) produced a high rate of complete pathologic response in patients with locally advanced vulvar...
HER2-Positive Early Breast Cancer: PET-Based, pCR-Adapted Strategy
In the phase II PHERGain trial reported in The Lancet, Pérez-García et al found that a positron-emission tomography (PET)-based, pathologic complete response (pCR)-adapted treatment strategy produced “excellent” 3-year invasive disease–free survival results in patients with HER2-positive early...
